Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: Results of a phase I/II study

Journal of Urology

Volumn 171, Issue 2 I, 2004, Pages 709-713

  Konety, Badrinath R ^a,c   Eastham, James A ^a,d   Reuter, Victor E ^a   Scardino, Peter T ^a   Donat, S Machele ^a   Dalbagni, Guido ^a   Russo, Paul ^a   Herr, Harry W ^a   Schwartz, Larry ^a   Kantoff, Philip W ^b   Scher, Howard ^a   Kelly, W Kevin ^a  

^a Department of Obstetrics Gynecology   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Drug therapy; Prostatectomy; Prostatic neoplasms

Indexed keywords

ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; CARBOPLATIN; ESTRAMUSTINE; GOSERELIN; HEPARIN; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NERVE GRAFT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SURGICAL TECHNIQUE;

EID: 9144221961     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000108122.36893.5a     Document Type: Article

References (19)

1. Lerner, S. E., Blute, M. L. and Zincke, H.: Extended experience with radical prostatectomy for clinical stage T3 prostate cancer: outcome and contemporary morbidity. J Urol, 154: 1447, 1995
2. van den Ouden, D., Hop, W. C. J. and Schröder, F. H.: Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy. J Urol, 160: 1392, 1998
3. Zagars, G. K., von Eschenbach, A. C. and Ayala, A. G.: Prognostic factors in prostate cancer. Analysis of 874 patients treated with radiation therapy. Cancer, 72: 1709, 1993
4. Zietman, A. L., Coen, J. J., Dallow, K. C. and Shipley, W. U.: The treatment of prostate cancer by conventional radiation therapy: an analysis of long-term outcome. Int J Radiat Oncol Biol Phys, 32: 287, 1995
5. D'Amico, A. V., Moul, J. W. and Kattan, M. W.: Emerging prognostic factors for outcome prediction in clinically localized prostate cancer: prostate-specific antigen level, race, molecular markers and neural networks. In: Genitourinary Oncology, 2nd ed. Edited by N. J. Vogelzang, P. T. Scardino, W. U. Shipley and D. S. Coffey. Philadelphia: Lippincott, Williams & Wilkins, pp. 681-697, 2000
6. Partin, A. W., Pound, C. R., Clemens, J. Q., Epstein, J. I. and Walsh, P. C.: Serum PSA after anatomic radical retropubic prostatectomy. The Johns Hopkins experience after 10 years. Urol Clin North Am, 20: 713, 1993
7. Soloway, M. S., Sharifi, R., Wajsman, Z., McLeod, D., Wood, D. P., Jr., Puras-Baez, A. et al: Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. J Urol, 154: 424, 1995
8. Goldenberg, S. L., Klotz, L. H., Srigley, J., Jewett, M. A. S., Mador, D., Fradet, Y. et al: Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. J Urol, 156: 873, 1996
9. Mettlin, C. J., Murphy, G. P., Rosenthal, D. S. and Menck, H. R.: The National Cancer Data Base report on prostate carcinoma after the peak incidence rates in the U.S. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer, 83: 1679, 1998
10. Hortobagyi, G. N.: Treatment of breast cancer. N Engl J Med, 339: 974, 1998
11. Minsky, B. D., Cohen, A. M., Kemeny, N., Enker, W. E., Kelsen, D. P., Reichman, B. et al: Enhancement of radiation-induced downstaging of rectal cancer by fluorouracil and high-dose leucovorin chemotherapy. J Clin Oncol, 10: 79, 1992
12. Zelefsky, M. J., Kelly, W. K., Sher, H. I., Lee, H., Smart, T., Metz, E. et al: Results of a phase II study using estramustine phosphate and vinblastine in combination with high-dose three-dimensional conformal radiotherapy for patients with locally advanced prostate cancer. J Clin Oncol, 18: 1936, 2000
13. Kelly, W. K., Curley, T., Slovin, S., Heller, G., McCaffrey, J., Bajorin, D. et al: Paclitaxel, estramustine phosphate, and carboplatin in patients with advance prostate cancer. J Clin Oncol, 19: 44, 2001
14. Kelly, W., Zhu, A., Curley, T., Fallon, M., Slovin, S., Rocchetti, M. et al: Intravenous (IV), estramustine (EMP), paclitaxel (T) and carboplatin (C), in patients with advanced prostate cancer (PC). Proc Am Soc Clin Oncol, 19: 347A, 2000
15. Kim, E. D., Scardino, P. T., Hampel, O., Mills, N. L., Wheeler, T. M. and Nath, R. K.: Interposition of sural nerve restores function of cavernous nerves resected during radical prostatectomy. J Urol, 161: 188, 1999
16. Kattan, M. W., Eastham, J. A., Stapleton, A. M., Wheeler, T. M. and Scardino, P. T.: A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst, 90: 766, 1998
17. Pettaway, C. A., Pisters, L. L., Troncoso, P., Slaton, J., Finn, L., Kamoi, K. et al: Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results. J Clin Oncol, 18: 1050, 2000
18. Clark, P. E., Peereboom, D. M., Dreicer, R., Levin, H. S., Clark, S. B. and Klein, E. A.: Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer. Urology, 57: 281, 2001
19. Lerner, S. E., Blute, M. L., Iocca, A. J. and Zincke, H.: Primary surgery for clinical stage T3 adenocarcinoma of the prostate. In: Genitourinary Oncology, 2nd ed. Edited by N. J. Vogelzang, P. T. Scardino, W. U. Shipley and D. S. Coffey. Philadelphia: Lippincott, Williams & Wilkins, pp. 789-799, 2000